AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie kaletra (lopinavir/ritonavir) [legacy through FY20Q1] — International net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2019
245
Period ended Dec 31, 2019
Change on a year earlier
-12.8%
281 in FY2018
History
4 years
Since FY2016
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kaletra (lopinavir/ritonavir) [legacy through FY20Q1] — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 245 | -12.8% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 281 | -20.2% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 352 | -18.7% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 433 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). AbbVie Kaletra (lopinavir/ritonavir) [legacy through FY20Q1] — International net revenues ($M) ($M), annual FY2016–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/kaletra_intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.